RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a

RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and 
Expansion Facility in Japan to Advance RCH-01, a
Treatment for Pattern Baldness 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 05/20/14 --  
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP) a
clinical stage regenerative medicine company focused on the
development of autologous cell therapies, is pleased to announce that
its RCH-01 licensing partner, Shiseido, celebrated the opening of its
new cell-processing facility at the Kobe Biomedical Innovation
Cluster (KBIC) located on Port Island, Japan on May 18, 2014.
Dignitaries, physicians, partner companies, and government
representatives were in attendance at this important event.
Shiseido's state-of-the-art facility will focus on the continued
research and development, and the commercialization of RepliCel's
RCH-01 hair regeneration technology. 
"Shiseido has been working diligently on the construction of their
facility and we congratulate them on their efficiency and commitment
to building a world-class cell research and development centre
capable of handling all aspects of the RCH-01 technology from hair
follicle biopsy through to cell replication and patient treatment,"
commented David M. Hall, CEO of RepliCel Life Sciences. "We continue
to support Shiseido with its highly focused development towards
commercialization of RCH-01 as a treatment for pattern baldness." 
The KBIC is a complex of medical-related industries located on the
833-hectare man-made island of Port Island in Kobe, Japan. Working in
cooperation with academic research institutions, government
organisations, and industry, the island has been developed as a focal
point for research and development of highly advanced medical
technologies with the goal of streamlining processes from research to
clinical application and commercialization. 
Regenerative medicine in Japan is an emerging industry which the
government has designated as an important part of its economic
reform. Legislative support has come from the introduction of new
laws to expedite otherwise lengthy clinical research and trial
application processes to promote competitive advantage in the
international market. In November 2013, as one of the new economic
reform strategies, the Japanese government passed the Regenerative
Medicine Law, which ensures safety of regenerative medicine, and
approved revisions to its existing Pharmaceutical Affairs Law to
improve the timelines for the development of regenerative medicine
and to promote commercialization. Shiseido has entered into this
field via its licensing agreement with RepliCel and is committed to
its advancement and success. 
Licensing Agreement 
On July 11, 2013, RepliCel and Shiseido announced the completion of a
Collaboration and Technology Transfer Agreement, giving Shiseido an
exclusive geographic license to use RCH-01 hair regeneration
technology in Japan, China, South Korea, Taiwan and the ASEAN
countries Shiseido and RepliCel will collaborate on the continued
improvement of the technology and will conduct human clinical trials
in each of their territories with the goal of commercializing a safe
and effective hair regenerative treatment to help those suffering
from pattern baldness and thinning hair. 
RCH-01 has been developed over 10 years of scientific research, and
safe application in humans was validated during RepliCel's phase 1
clinical trial. RepliCel has patents issued for hair follicle
mesenchymal stem cells and their usage in Japan, the United States,
Australia and the EU. RCH-01 is an autologous cell-based hair
regenerative technology whereby specific hair follicle cells are
isolated from a scalp biopsy, expanded in culture at a cell
processing facility and injected back into patients. 
About the Kobe Biomedical Innovation Cluster and Shiseido's Facility 
More than 260 domestic and international companies have built R&D
facilities focusing on regenerative medicine, pharmaceuticals,
medical equipment and devices in the research park, taking advantage
of the opportunities for collaboration and synergy that the KBIC
fosters. Centralised support services facilitate clinical research,
commercialisation, consultations on pharmaceutical development issues
and financing, and the establishment of comprehensive platforms for
biomedical research and development. The Business Support Centre for
Biomedical Research Activities has been built to support and to
provide space for research and commercialization of regenerative
medicine. This facility is divided into two sections, research and
cell-processing. Shiseido's Cell-Processing and Expansion Centre
(SPEC) is located in the cell processing section, Room 620, 1-5-5
Minamimachi, Minatojima, Chuoku, Kobe, 650-0047, Japan. 
About RepliCel Life Sciences 
RepliCel is a regenerative medicine company focused on developing
autologous cell therapies that treat functional cellular deficits
including chronic tendinosis, pattern baldness and skin aging.
Initiation of Phase 2 trials are planned for 2014 on RepliCel's
RCT-01 treatment for Achilles tendinosis and RCH-01 treatment for
pattern baldness. Shiseido Company, Limited has an exclusive
geographic license for RCH-01 in certain Asian countries including
Japan, China and South Korea. Both product candidates are based on
RepliCel's innovative technology which utilizes cells isolated from a
patient's own healthy hair follicles to address specific cellular
deficits. These products are built on the company's proprietary
manufacturing platforms. For additional information please visit
www.replicel.com. 
Neither the TSX Venture Exchange Inc. nor its Regulation Service
Provider (as that term is defined in the policies of the TSX Venture
Exchange Inc.) accepts responsibility for the adequacy or accuracy of
this press release. 
This press release contains forward-looking information that involve
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation statements
based on current expectations involving a number of risks and
uncertainties and are not guarantees of future performance of
RepliCel, such as the statement that RepliCel is seeking additional
financing. There are numerous risks and uncertainties that could
cause actual results and RepliCel's plans and objectives to differ
materially from those expressed in the forward-looking information,
including: (i) adverse market conditions; (ii) the inability of
RepliCel to complete the private placement at all or on the terms
announced; or (iii) the TSX Venture Exchange not approving further
private placements. Actual results and future events could differ
materially from those anticipated in such information. These and all
subsequent written and oral forward-looking information are based on
estimates and opinions of management on the dates they are made and
are expressly qualified in their entirety by this notice. Except as
required by law, RepliCel does not intend to update these
forward-looking statements. 
Contacts:
COMPANY CONTACTS:
David M. Hall, Chief Executive Officer
Tammey George, Director of Communications
RepliCel Life Sciences
604-248-8696
tg@replicel.com 
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
 
 
Press spacebar to pause and continue. Press esc to stop.